



Division of  
Johnson & Johnson  
Vision Care, Inc.

RECEIVED  
CENTRAL FAX CENTER

MAY 13 2004

**CONFIDENTIAL**  
**FACSIMILE TRANSMISSION SHEET**

OFFICIAL

**DATE:** May 13, 2004  
**TO:** Examiner Rachel M. Bennett  
Art Unit 1615  
**FAX:** 703-872-9306  
**FROM:** Karen Harding, Patent Attorney  
**PHONE:** 904-443-3074  
**FAX #:** 904-443-3078  
**Re:** Response to 2-13-04 Office Action  
Serial Number: 10/029,526  
Our Docket Number: VTN 570

Please see attached.

**Total Pages Sent:** 4 (including this cover sheet)

Please call Kate Willan at 443-1159 if you do not receive all of the pages in this transmission. Thank you.

This facsimile transmission cover sheet and any documents which may accompany it, contains information from Vistakon®, Division of Johnson & Johnson Vision Care, Inc., which is intended only for the use of the individual or entity to which it is addressed, and which may contain information that is privileged, confidential and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us collect to arrange for the destruction of the communication or its return to us at our expense.

*Note: refax - Title on the fist page of  
the prior fax was incorrect.*

Docket No. VTN-570

RECEIVED  
CENTRAL FAX CENTER

MAY 13 2004

OFFICIAL

Applicants : David C. Turner, et al.  
Serial No. : 10/029,526  
Filed : December 21, 2001  
Title: ANTIMICROBIAL LENSES AND METHODS OF THEIR USE  
Art Unit : 1615  
Examiner : Rachel M. Bennett

I hereby certify that this correspondence is being facsimile transmitted  
to the Patent and Trademark Office, Fax No. (703) 872-9306 on

May 13, 2004  
(Date of Deposit)

Karen Harding  
Name of applicant, assignee, or Registered Representative

(Signature)

May 13, 2004  
(Date of Signature)

Honorable Commissioner of Patents  
Washington, D.C. 20231

Response under 35 CFR 1.111

Dear Sir:

Amendments to the Claims there are no amendments to the claims.

Remarks/Arguments begin on page 2 of this paper.